Onconetix, Inc. (ONCO)
| Market Cap | 2.60M |
| Revenue (ttm) | 58,465 |
| Net Income (ttm) | -37.41M |
| Shares Out | 22.32M |
| EPS (ttm) | -2.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 156,180 |
| Open | 0.120 |
| Previous Close | 0.120 |
| Day's Range | 0.113 - 0.122 |
| 52-Week Range | 0.100 - 1.580 |
| Beta | 3.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 10, 2024 |
About ONCO
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide prot... [Read more]
Financial Performance
Financial StatementsNews
Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors
CINCINNATI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therape...
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company's Chief Executive Officer, Dr...
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer Transaction strengthens commercial business with addition of diagnostics product a...
Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company
Transaction will Advance Company's Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team Transaction will Advance Company's Shift in Business Strategy Aligned...
Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)
CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq")...
Blue Water Biotech Issues Letter to Shareholders
CINCINNATI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today issued the following shareholder letter from the Company's Chief Executive Officer D...
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), which is focused on developing and commercializing transformational therapies to address significant global health...
Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q
CINCINNATI, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical company spanning multiple sectors, today announced that it re...
Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
CINCINNATI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), today announced the closing of its previously announced exercise of certain existi...
Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
CINCINNATI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the “Company”) (Nasdaq: BWV), today announced it has entered into a definitive agreement for the exercise of cer...
Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians
CINCINNATI, July 31, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializi...
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializi...
Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities
CINCINNATI, July 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializi...
Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support
Pharmaceutical consulting firm to provide Blue Water with access to healthcare payers and PBMs Pharmaceutical consulting firm to provide Blue Water with access to healthcare payers and PBMs
Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products
First state license is a key achievement as Blue Water continues to expand its business into commercial activities First state license is a key achievement as Blue Water continues to expand its busine...
Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio
CINCINNATI, July 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializi...
Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform
CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today ...
Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio
CINCINNATI, June 21, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today announ...
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
CINCINNATI, Ohio, June 14, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), a biotechnology company spanning multiple sectors, today announced the signing of an Asset Purchase Agreemen...
Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights
CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced its financial results for the ...
Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY
CINCINNATI, May 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global h...
Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer
CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced the appointment of Jay Newma...
Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®
CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced that Blue Water management w...
Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company
CINCINNATI, April 24, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global...
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference call...